-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma releases 2025 ESG report

PUBT·04/27/2026 23:23:27
Listen to the news
Ascentage Pharma releases 2025 ESG report
  • Ascentage Pharma issued its 2025 environmental, social, and governance report, highlighting RMB 1.14 billion of R&D investment.
  • Intellectual property portfolio reached 512 authorized patents worldwide by end of 2025.
  • Regulatory momentum included 16 FDA orphan drug designations across four investigational drugs, plus one orphan designation in EU.
  • Manufacturing footprint secured ISO 9001 quality certification across 100% of production facilities, with zero safety-related product recalls.
  • Environmental and safety systems covered 100% of production bases under ISO 14001, with no environmental pollution incidents or administrative penalties reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12126983), on April 27, 2026, and is solely responsible for the information contained therein.